- Report
- February 2025
- 85 Pages
India
From €3340EUR$3,500USD£2,799GBP
- Report
- October 2023
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 180 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- February 2024
- 114 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 184 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Drug Pipelines
- January 2024
- 70 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2023
- 220 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- October 2022
- 200 Pages
Global
From €2815EUR$2,950USD£2,359GBP
- Report
- January 2024
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- March 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- February 2024
- 179 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- July 2023
- 115 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- April 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- December 2023
- 100 Pages
Africa
From €1909EUR$2,000USD£1,599GBP
- Report
- December 2023
- 80 Pages
United Kingdom
From €1432EUR$1,500USD£1,199GBP
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
Poland
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
Argentina
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
Brazil
From €1432EUR$1,500USD£1,199GBP

RNAi therapy is a type of biotechnology that uses small pieces of RNA to target and silence specific genes. This technology has been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. RNAi therapy works by introducing small interfering RNAs (siRNAs) into cells, which then bind to and degrade messenger RNAs (mRNAs) that encode for specific proteins. This process can be used to reduce the expression of disease-causing genes, or to activate beneficial genes.
RNAi therapy has the potential to revolutionize the treatment of many diseases, as it is a more precise and targeted approach than traditional drug therapies. It is also less toxic and has fewer side effects. However, the development of RNAi therapies is still in its early stages, and there are many challenges that need to be addressed before they can be widely used in clinical settings.
Some companies in the RNAi therapy market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Show Less Read more